Wells Fargo Lowers Price Target for Amphastar Pharmaceuticals Stock

Analysts cite reduced expectations for the pharmaceutical company's performance.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Wells Fargo & Company has lowered its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) stock from $34.00 to $30.00. The brokerage firm maintained an 'overweight' rating on the stock, but the reduced target suggests a potential upside of 35.29% from the stock's previous close. Other analysts have also issued mixed ratings on Amphastar, with some maintaining 'hold' recommendations.

Why it matters

Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on the development, manufacturing, and commercialization of injectable and inhalation products. The company's stock performance and analyst ratings can impact investor sentiment and the overall outlook for the business.

The details

In its report, Wells Fargo cited reduced expectations for Amphastar's performance as the reason for the lower price target. The brokerage firm currently has an 'overweight' rating on the stock. Other analysts have also issued mixed ratings, with Zacks Research lowering its rating to 'hold' and Weiss Ratings maintaining a 'hold (c-)' rating. Barclays assumed coverage on Amphastar with an 'equal weight' rating and a $30.00 price target.

  • The report was issued on Friday, February 27, 2026.

The players

Wells Fargo & Company

A major American multinational financial services company.

Amphastar Pharmaceuticals

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California, that focuses on the development, manufacturing, and commercialization of injectable and inhalation products.

Zacks Research

A research firm that provides investment research and analysis.

Weiss Ratings

A financial research and ratings agency.

Barclays

A British multinational investment bank and financial services company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The lowered price target for Amphastar Pharmaceuticals stock by Wells Fargo reflects the broader market's mixed outlook on the company's performance, with some analysts maintaining a cautious stance. This highlights the need for investors to closely monitor the company's financial results and strategic initiatives as it navigates the competitive pharmaceutical landscape.